Selenoprotein p for prediction of a first cardiovascular event
AssigneeSphingotec GmbH
InventorsAndreas BERGMANN, Olle MELANDER
Life of this patent
Estimating the term…
Abstract
Subject of the present invention is a method for assessing a risk for getting a first cardiovascular event or assessing the risk for cardiovascular mortality in a subject, comprising: a) determining the level and/or the amount of Selenoprotein P and/or fragments thereof in a sample of said subject; b) correlating the determined level and/or the amount of Selenoprotein P and/or fragments thereof with the risk for getting a first cardiovascular event or assessing the risk for cardiovascular mortality in said subject.
Claims25
A method for assessing a risk for getting a first cardiovascular event or assessing the risk for cardiovascular mortality in a subject, comprising
- a) determining the level and/or the amount of Selenoprotein P and/or fragments thereof in a sample of said subject
- b) correlating the determined level and/or the amount of Selenoprotein P and/or fragments thereof with the risk for getting a first cardiovascular event or assessing the risk for cardiovascular mortality in said subject
A method for assessing a risk for getting a first cardiovascular event or assessing the risk for cardiovascular mortality in a subject according to claim wherein the risk for getting a first cardiovascular event or assessing the risk for cardiovascular mortality is enhanced when said level and/or the amount of Selenoprotein P and/or fragments thereof in said sample is below a threshold, wherein said threshold has been determined by the calculation of receiver operating characteristic curves (ROC curves), plotting the value of a variable versus its relative frequency in the “normal” population (e.g. subjects who did not develop the condition) and “disease” population (e.g. subjects who did develop the condition).
A method for assessing a risk for getting a first cardiovascular event or assessing the risk for cardiovascular mortality in a subject according to claim wherein said subject has never had a cardiovascular event and has never had any cardiovascular disease at the time of sample taking.
A method for assessing a risk for getting a first cardiovascular event or assessing the risk for cardiovascular mortality in a subject according to claim wherein said subject does not suffer from diabetes mellitus.
(canceled)
(canceled)
(canceled)
(canceled)
A kit comprising nicotinic consumables and a solid composition comprising selenium.
A method of treatment of a subject having a risk for getting a first cardiovascular event or a risk for cardiovascular mortality, wherein selenium is administered to said subject in a pharmaceutically acceptable amount said subject has an enhanced risk for getting a first cardiovascular event or a risk for cardiovascular mortality.
Dependencies are inferred from the claim text.